325 related articles for article (PubMed ID: 28767654)
1. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.
Prabhu VV; Lulla AR; Madhukar NS; Ralff MD; Zhao D; Kline CLB; Van den Heuvel APJ; Lev A; Garnett MJ; McDermott U; Benes CH; Batchelor TT; Chi AS; Elemento O; Allen JE; El-Deiry WS
PLoS One; 2017; 12(8):e0180541. PubMed ID: 28767654
[TBL] [Abstract][Full Text] [Related]
2. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
[TBL] [Abstract][Full Text] [Related]
3. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
[TBL] [Abstract][Full Text] [Related]
4. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
Prabhu VV; Talekar MK; Lulla AR; Kline CLB; Zhou L; Hall J; Van den Heuvel APJ; Dicker DT; Babar J; Grupp SA; Garnett MJ; McDermott U; Benes CH; Pu JJ; Claxton DF; Khan N; Oster W; Allen JE; El-Deiry WS
Cell Cycle; 2018; 17(4):468-478. PubMed ID: 29157092
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS
Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985
[TBL] [Abstract][Full Text] [Related]
6. Discovery and clinical introduction of first-in-class imipridone ONC201.
Allen JE; Kline CL; Prabhu VV; Wagner J; Ishizawa J; Madhukar N; Lev A; Baumeister M; Zhou L; Lulla A; Stogniew M; Schalop L; Benes C; Kaufman HL; Pottorf RS; Nallaganchu BR; Olson GL; Al-Mulla F; Duvic M; Wu GS; Dicker DT; Talekar MK; Lim B; Elemento O; Oster W; Bertino J; Flaherty K; Wang ML; Borthakur G; Andreeff M; Stein M; El-Deiry WS
Oncotarget; 2016 Nov; 7(45):74380-74392. PubMed ID: 27602582
[TBL] [Abstract][Full Text] [Related]
7. The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma.
Tu YS; He J; Liu H; Lee HC; Wang H; Ishizawa J; Allen JE; Andreeff M; Orlowski RZ; Davis RE; Yang J
Neoplasia; 2017 Oct; 19(10):772-780. PubMed ID: 28863346
[TBL] [Abstract][Full Text] [Related]
8. Role of Dopamine Receptors in the Anticancer Activity of ONC201.
Kline CLB; Ralff MD; Lulla AR; Wagner JM; Abbosh PH; Dicker DT; Allen JE; El-Deiry WS
Neoplasia; 2018 Jan; 20(1):80-91. PubMed ID: 29216597
[TBL] [Abstract][Full Text] [Related]
9. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo.
Jhaveri AV; Zhou L; Ralff MD; Lee YS; Navaraj A; Carneiro BA; Safran H; Prabhu VV; Ross EA; Lee S; El-Deiry WS
Cancer Biol Ther; 2021 Dec; 22(10-12):607-618. PubMed ID: 34856854
[TBL] [Abstract][Full Text] [Related]
10. ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer.
Lev A; Lulla AR; Ross BC; Ralff MD; Makhov PB; Dicker DT; El-Deiry WS
Mol Cancer Res; 2018 May; 16(5):754-766. PubMed ID: 29588330
[TBL] [Abstract][Full Text] [Related]
11. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.
Talekar MK; Allen JE; Dicker DT; El-Deiry WS
Cell Cycle; 2015 Aug; 14(15):2422-8. PubMed ID: 26030065
[TBL] [Abstract][Full Text] [Related]
12. Microarray analysis reveals ONC201 mediated differential mechanisms of CHOP gene regulation in metastatic and nonmetastatic colorectal cancer cells.
Al Madhoun A; Haddad D; Al Tarrah M; Jacob S; Al-Ali W; Nizam R; Miranda L; Al-Rashed F; Sindhu S; Ahmad R; Bitar MS; Al-Mulla F
Sci Rep; 2021 Jun; 11(1):11893. PubMed ID: 34088951
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
[TBL] [Abstract][Full Text] [Related]
14. Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study.
Feng Y; Zhou J; Li Z; Jiang Y; Zhou Y
PLoS One; 2016; 11(9):e0162133. PubMed ID: 27626799
[TBL] [Abstract][Full Text] [Related]
15. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
[TBL] [Abstract][Full Text] [Related]
16. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.
Wang D; Fu L; Sun H; Guo L; DuBois RN
Gastroenterology; 2015 Dec; 149(7):1884-1895.e4. PubMed ID: 26261008
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Id1-Kif11 Axis in Triple-Negative Breast Cancer Using Combination Therapy.
Thankamony AP; Murali R; Karthikeyan N; Varghese BA; Teo WS; McFarland A; Roden DL; Holliday H; Konrad CV; Cazet A; Dodson E; Yang J; Baker LA; George JT; Levine H; Jolly MK; Swarbrick A; Nair R
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32911668
[TBL] [Abstract][Full Text] [Related]
18. First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent.
Allen JE; Crowder RN; El-Deiry WS
PLoS One; 2015; 10(11):e0143082. PubMed ID: 26580220
[TBL] [Abstract][Full Text] [Related]
19. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
Allen JE; Krigsfeld G; Patel L; Mayes PA; Dicker DT; Wu GS; El-Deiry WS
Mol Cancer; 2015 May; 14():99. PubMed ID: 25927855
[TBL] [Abstract][Full Text] [Related]
20. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.
Wagner J; Kline CL; Zhou L; Campbell KS; MacFarlane AW; Olszanski AJ; Cai KQ; Hensley HH; Ross EA; Ralff MD; Zloza A; Chesson CB; Newman JH; Kaufman H; Bertino J; Stein M; El-Deiry WS
J Clin Invest; 2018 Jun; 128(6):2325-2338. PubMed ID: 29533922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
